![Frontiers | Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy Frontiers | Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy](https://www.frontiersin.org/files/Articles/656444/fonc-11-656444-HTML/image_m/fonc-11-656444-t003.jpg)
Frontiers | Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy
Clinical Case Discussions - Rising PSA 18 Months Post RP and Timing of Radiotherapy | Rising PSA 18 months post-RP & timing of radiotherapy. Ashley Ross, MD, PhD Northwestern University Feinberg School
![Tissue PSA distribution across the prostate gland at t = 0.5 y, tumor... | Download Scientific Diagram Tissue PSA distribution across the prostate gland at t = 0.5 y, tumor... | Download Scientific Diagram](https://www.researchgate.net/publication/310585827/figure/fig4/AS:431670072483843@1479929573889/Tissue-PSA-distribution-across-the-prostate-gland-at-t-05-y-tumor-volume-evolution.png)
Tissue PSA distribution across the prostate gland at t = 0.5 y, tumor... | Download Scientific Diagram
![Frontiers | Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy Frontiers | Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy](https://www.frontiersin.org/files/Articles/656444/fonc-11-656444-HTML/image_m/fonc-11-656444-t001.jpg)
Frontiers | Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy
![Race-Specific Trends in Prostate Cancer Screening and Presentation before and after the 2012 United States Preventive Services Task Force Statement | Urology Practice Race-Specific Trends in Prostate Cancer Screening and Presentation before and after the 2012 United States Preventive Services Task Force Statement | Urology Practice](https://www.auajournals.org/cms/asset/c7560027-7ce5-4009-b22c-828894a62298/upj.0000000000000274f1.gif)
Race-Specific Trends in Prostate Cancer Screening and Presentation before and after the 2012 United States Preventive Services Task Force Statement | Urology Practice
Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy | PLOS ONE
![Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer | BMC Research Notes | Full Text Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer | BMC Research Notes | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13104-021-05641-5/MediaObjects/13104_2021_5641_Fig1_HTML.png)
Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer | BMC Research Notes | Full Text
![Cancers | Free Full-Text | Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide Cancers | Free Full-Text | Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide](https://www.mdpi.com/cancers/cancers-14-02219/article_deploy/html/images/cancers-14-02219-g003.png)
Cancers | Free Full-Text | Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
![Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer | Journal of Clinical Oncology Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2016/jco.2015.65.34.issue-23/jco.2016.66.7527/20161107/images/medium/jco667527t2.gif)
Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer | Journal of Clinical Oncology
![ESMO 2022: Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial ESMO 2022: Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial](https://larvolclin.s3.us-west-2.amazonaws.com/resize_166306090938969400863204badaece6.png)
ESMO 2022: Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial
![Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future | Nature Reviews Urology Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future | Nature Reviews Urology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41585-022-00638-6/MediaObjects/41585_2022_638_Fig1_HTML.png)
Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future | Nature Reviews Urology
![Predicting the risk of prostate cancer in asymptomatic men: a cohort study to develop and validate a novel algorithm | British Journal of General Practice Predicting the risk of prostate cancer in asymptomatic men: a cohort study to develop and validate a novel algorithm | British Journal of General Practice](https://bjgp.org/content/bjgp/71/706/e364/F1.large.jpg)